Composition, form of production and packaging
Tablets are white, flat-cylindrical, with a facet and a risk.
1 tab.
calcium gopantenate (gopantenic acid or calcium salt of gopantenic acid) 250 mg
Excipients: magnesium hydroxycarbonate - 46.77 mg, calcium stearate - 3.1 mg, talc - 62 mg, potato starch - 3.93 mg.
10 pieces. - Packings contour mesh (5) - packs cardboard.
50 pcs. - polymer cans (1) - packs of cardboard.
Tablets are white, flat-cylindrical, with a facet and a risk.
1 tab.
calcium gopantenate (gopantenic acid or calcium salt of gopantenic acid) 500 mg
Excipients: magnesium hydroxycarbonate - 93.54 mg, calcium stearate - 6.2 mg, talc - 12.4 mg, potato starch - 7.86 mg.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
50 pcs. - cans (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
PHARMACHOLOGIC EFFECT
Nootropic preparation. The spectrum of action is related to the presence of GABA in the structure. The mechanism of action is due to the direct influence of pantocalcin on the GABA B- receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties.
Increases brain resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons.
Has an anticonvulsant effect, reduces motor excitability with simultaneous ordering of behavior. Increases mental and physical performance. Helps normalize the GABA content in chronic alcohol intoxication and subsequent ethanol elimination. Has an analgesic effect.
The drug is able to inhibit the acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter.
It causes inhibition of the pathologically increased vesicle reflex and detrusor tone.
PHARMACOKINETICS
Suction
Quickly absorbed from the digestive tract. The time to reach C max in blood plasma is 1 hour.
Distribution and Metabolism
The greatest concentrations are created in the liver, kidneys, in the wall of the stomach, the skin. Penetrates through the BBB. It is not metabolized.
Excretion
It is unchanged for 48 hours (67.5% of the dose taken with urine, 28.5% with feces).
INDICATIONS
- cognitive impairment with organic brain lesions and neurotic disorders;
- as part of a comprehensive therapy for cerebrovascular insufficiency caused by atherosclerotic changes in cerebral vessels; senile dementia (initial form), residual organic brain damage in persons of mature age and elderly;
- cerebral organic insufficiency in patients with schizophrenia (in combination with neuroleptics, antidepressants);
- extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (including Huntington's chorea, hepatocerebral dystrophy, Parkinson's disease);
- consequences of the transferred neuroinfections and craniocerebral traumas (as part of complex therapy);
- for the correction of side effects of neuroleptics and with a preventive purpose at the same time as "cover therapy";
- Extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic);
- epilepsy with a slowing of mental processes (in combination with anticonvulsant drugs);
- psycho-emotional overload, reduced mental and physical performance; to improve concentration and memorization;
- disorders of urination: enuresis, daytime urinary incontinence, pollakiuria, imperative urges;
- Children with mental retardation (delay in mental, speech, motor development or their combination), infantile cerebral palsy, stuttering (mostly clonic form), epilepsy (as part of combination therapy with anticonvulsant drugs, especially in polymorphic attacks and small epileptic seizures).
DOSING MODE
The drug is administered orally, 15-30 minutes after eating.
A single dose for adults is 0.5-1 g, for children - 250-500 mg; The daily dose for adults is 1.5-3 g, for children 0.75-3 g. The duration of the course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a second course of treatment is possible.
Children with mental deficiency appoint 0.5 g 4-6 times / day daily for 3 months; at a delay of speech development - on 500 mg 3-4 times / sut within 2-3 months.
With neuroleptic syndrome (as an adjunct to the side effects of neuroleptic drugs), adults are prescribed 0.5-1 g 3 times / day; children - 250-500 mg 3-4 times / day.Course of treatment -1-3 months.
In epilepsy, adults are prescribed 0.5-1 g 3-4 times / day; children - 250-500 mg 3-4 times / day. The drug is taken daily for a long time (up to 6 months).
In hyperkinesis (tics), adults are prescribed 1.5-3 g / day daily for 1-5 months; children are prescribed 250-500 mg 3-6 times a day daily for 1-4 months.
In disorders of urination, adults are prescribed 0.5-1 g 2-3 times / day, a daily dose of 2-3 g; children - 250-500 mg daily dose - 25-50 mg / kg. The course of treatment is from 2 weeks to 3 months (depending on the severity of the disorders and the therapeutic effect).
At the consequences of neuroinfections and craniocerebral traumas , 250 mg 3-4 times / day are prescribed.
To restore working capacity under increased loads and asthenic conditions , 250 mg 3 times / day are prescribed.
SIDE EFFECT
Allergic reactions: rhinitis, conjunctivitis, skin rashes.
CONTRAINDICATIONS
acute renal failure;
- I trimester of pregnancy;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
Pantocalcin В® is contraindicated in the first trimester of pregnancy.
Data on the safety of the drug in the II and III trimesters of pregnancy and lactation are not provided.
APPLICATION FOR FUNCTIONS OF THE LIVER
The drug is contraindicated in acute kidney failure.
APPLICATION FOR CHILDREN
This dosage form of the drug is not recommended for children under the age of 3 years .
SPECIAL INSTRUCTIONS
This dosage form of the drug is not recommended for children under the age of 3 years .
OVERDOSE
Data on the overdose of Pantocalcin В® are not available.
DRUG INTERACTION
Pantokalcin В® prolongs the action of barbiturates, enhances the effects of drugs that stimulate the central nervous system, anticonvulsants, the action of local anesthetics (procaine).
Prevents the side effects of phenobarbital, carbamazepine, antipsychotic drugs (neuroleptics).
The action of gopanthenic acid is enhanced in combination with glycine, xyediphon.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 4 years.
